Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Aug 31 · below the Ichimoku cloud · RSI 25 (oversold) · MACD below its signal · at its 52-week low
None of the 29 investors followed here reported a position in ZEAL.CO in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a ZEAL.CO trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for ZEAL.CO.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -9.9 | -13.4 | -18.9 | 1.5 | 8.5 | -10.9 | 5.0 | -1.3 | -9.6 | -15.6 | −50.9% | ||
| 2025 | 2.8 | -9.9 | -22.0 | -10.7 | -1.8 | -21.8 | -3.1 | 27.3 | 5.4 | 11.2 | 0.7 | -9.7 | −34.8% |
| 2024 | 26.5 | 40.6 | 2.6 | -7.1 | 1.0 | 39.6 | 4.2 | -4.7 | -8.3 | -2.8 | -7.7 | -2.0 | +91.7% |
| 2023 | 5.7 | 5.5 | -4.3 | 6.2 | 16.8 | -8.3 | -3.7 | 9.0 | 19.1 | -4.3 | 14.8 | 11.1 | +85.3% |
| 2022 | -11.6 | -20.6 | 2.3 | -22.8 | 22.8 | -6.0 | 41.2 | 0.9 | 31.5 | 11.7 | 3.7 | 0.0 | +38.8% |
| 2021 | -10.6 | -1.1 | 2.8 | 1.2 | -9.3 | 0.6 | 2.6 | 2.1 | -4.6 | 11.4 | -33.8 | 6.5 | −34.2% |
| 2020 | 3.9 | -1.2 | -3.3 | 1.1 | 11.8 | -13.9 | -4.0 | 9.0 | 1.5 | -11.8 | 11.8 | -7.5 | −6.3% |
| 2019 | 14.4 | 2.8 | 22.6 | 15.4 | 0.1 | 3.9 | 6.4 | -14.7 | 34.7 | 14.4 | 4.5 | 12.8 | +185.7% |
| 2018 | 19.5 | -6.8 | -1.7 | 0.1 | 3.1 | -12.6 | 13.2 | -2.7 | 13.7 | -20.2 | -1.8 | 0.0 | −3.1% |
| 2017 | 9.4 | -1.3 | -2.2 | 8.4 | -2.5 | 9.7 | -4.2 | -4.8 | 2.1 | -2.9 | -25.0 | -4.0 | −20.2% |
| 2016 | -16.5 | -5.1 | 12.5 | -4.4 | -3.9 | -3.6 | 8.4 | -13.5 | -12.1 | -4.6 | 17.0 | -3.2 | −29.7% |
| 2015 | 3.0 | -3.5 | 26.1 | -12.0 | 18.0 | 2.3 | 34.4 | -11.4 | 11.4 | 3.4 | -0.7 | 0.7 | +82.5% |
| 2014 | 24.6 | 2.7 | -8.6 | -3.6 | -4.5 | 10.2 | 2.9 | -1.4 | -2.8 | -1.4 | -1.5 | 23.9 | +40.7% |
| 2013 | 13.1 | -17.4 | 3.8 | -4.9 | -7.7 | -3.5 | 8.7 | -14.0 | -10.9 | 7.8 | 0.8 | -5.6 | −29.8% |
| 2012 | 7.9 | 14.6 | 18.4 | 32.9 | -24.3 | -4.8 | 10.0 | 5.7 | 6.5 | 4.5 | -7.2 | -12.5 | +47.4% |
| 2011 | 0.0 | -4.3 | 3.7 | 0.7 | 1.4 | 1.4 | -5.6 | -18.4 | -10.1 | 2.2 | -1.0 | 12.9 | −18.6% |
| 2010 | -14.6 | −14.6% |
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.
Buy / hold / sell counts
No recent headlines.